Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP46A1 | Q9Y6A2 | 10/20 | 0.76 |
| ▸ | MAPT | P10636 | 2/20 | 0.76 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.76 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.76 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.76 |
| ▸ | PGR | P06401 | 1/20 | 0.76 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.76 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.76 |
| ▸ | CNR1 | P21554 | 1/20 | 0.76 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.76 |
| ▸ | HTR2A | P28223 | 1/20 | 0.76 |
| ▸ | HTR2C | P28335 | 1/20 | 0.76 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.76 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.76 |
| ▸ | CCKBR | P32239 | 1/20 | 0.76 |
| ▸ | PPARG | P37231 | 1/20 | 0.76 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.76 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.76 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.76 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12470341 | 1.00 | CYP46A1 (0.76) | CYP46A1MAPTNPSR1NR1I2NR3C1 | |
| SCHEMBL2625353 | 0.87 | CYP46A1 (0.77) | CYP46A1MAPTNPSR1NR1I2NR3C1 | |
| SCHEMBL1702633 | 0.87 | CYP46A1 (0.77) | CYP46A1MAPTNPSR1NR1I2NR3C1 | |
| SCHEMBL1702634 | 0.87 | CYP46A1 (0.77) | CYP46A1MAPTNPSR1NR1I2NR3C1 | |
| SCHEMBL9925910 | 0.86 | CYP46A1 (0.76) | CYP46A1MAPTNPSR1NR1I2NR3C1 | |
| SCHEMBL19236427 | 0.86 | CYP46A1 (0.76) | CYP46A1MAPTNPSR1NR1I2NR3C1 | |
| SCHEMBL3817561 | 0.86 | CYP46A1 (0.76) | CYP46A1MAPTNPSR1NR1I2NR3C1 | |
| Efavirenz SCHEMBL3227745 | 0.86 | CYP46A1 (1.00) | CYP46A1MAPTNPSR1NR1I2NR3C1 | |
| Efavirenz SCHEMBL464769 | 0.86 | CYP46A1 (1.00) | CYP46A1MAPTNPSR1NR1I2NR3C1 | |
| Efavirenz SCHEMBL13098636 | 0.86 | CYP46A1 (1.00) | CYP46A1MAPTNPSR1NR1I2NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230172902-A1 | METHODS FOR THE PROPHYLAXIS AND TREATMENT OF COVID AND COVID-19 | TRAN LLOYD HUNG LOI (US) | 2023-06-08 | — | — | US | disclosed |
| EP-2627627-B1 | PROCESS FOR THE SYNTHESIS OF CHIRAL PROPARGYLIC ALCOHOLS | BRISTOL MYERS SQUIBB CO (US) | 2017-08-09 | — | — | EP | disclosed |
| EP-2627643-B1 | PROCESS FOR THE SYNTHESIS OF CYCLIC CARBAMATES | BRISTOL MYERS SQUIBB CO (US) | 2016-11-23 | — | — | EP | disclosed |
| US-20160326101-A1 | Process for the Synthesis of Chiral Propargylic Alcohols | BRISTOL MYERS SQUIBB CO (US) | 2016-11-10 | — | — | US | disclosed |
| US-8993262-B2 | In vivo and in vitro olefin cyclopropanation catalyzed by heme enzymes | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2015-03-31 | — | — | US | disclosed |
| US-8969550-B2 | Process for the synthesis of cyclic carbamates | LONZA LTD. (CH) | 2015-03-03 | — | — | US | disclosed |
| US-8957204-B2 | Process for the synthesis of cyclic carbamates | LONZA LTD. (CH) | 2015-02-17 | — | — | US | disclosed |
| EP-2627642-B1 | PROCESS FOR THE SYNTHESIS OF CYCLIC CARBAMATES | LONZA AG (CH) | 2014-12-24 | — | — | EP | disclosed |
| US-20140242647-A1 | IN VIVO AND IN VITRO OLEFIN CYCLOPROPANATION CATALYZED BY HEME ENZYMES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2014-08-28 | — | — | US | disclosed |
| US-20130324763-A1 | PROCESS FOR THE SYNTHESIS OF CHIRAL PROPARGYLIC ALCOHOLS | LONZA LTD (CH) | 2013-12-05 | — | — | US | disclosed |
| US-20130217875-A1 | PROCESS FOR THE SYNTHESIS OF CYCLIC CARBAMATES | LONZA LTD (CH) | 2013-08-22 | — | — | US | disclosed |
| EP-2627643-A1 | PROCESS FOR THE SYNTHESIS OF CYCLIC CARBAMATES | Lonza Ltd (CH) | 2013-08-21 | — | — | EP | disclosed |
| EP-2627642-A1 | PROCESS FOR THE SYNTHESIS OF CYCLIC CARBAMATES | Lonza Ltd (CH) | 2013-08-21 | — | — | EP | disclosed |
| US-20130211077-A1 | PROCESS FOR THE SYNTHESIS OF CYCLIC CARBAMATES | LONZA LTD (CH) | 2013-08-15 | — | — | US | disclosed |
| WO-2012048886-A1 | PROCESS FOR THE SYNTHESIS OF CYCLIC CARBAMATES | LONZA LTD (CH) | 2012-04-19 | — | — | WO | disclosed |
| WO-2012048884-A1 | PROCESS FOR THE SYNTHESIS OF CYCLIC CARBAMATES | LONZA LTD (CH) | 2012-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160326101-A1 | Process for the Synthesis of Chiral Propargylic Alcohols | ADH1C, ADH1A, ADH5 | CYP46A1 1175/4885MAPT 2493/4885NPSR1 2214/4885 |
| US-20130217875-A1 | PROCESS FOR THE SYNTHESIS OF CYCLIC CARBAMATES | PLCG2, PLCG1, CPS1 | CYP46A1 2876/4885MAPT 4313/4885NPSR1 2972/4885 |
| US-20230172902-A1 | METHODS FOR THE PROPHYLAXIS AND TREATMENT OF COVID AND COVID-19 | ACE, ACE2, LPO | CYP46A1 899/4885MAPT 1277/4885NPSR1 2283/4885 |
| US-20130324763-A1 | PROCESS FOR THE SYNTHESIS OF CHIRAL PROPARGYLIC ALCOHOLS | ADH1C, ADH1A, ADH5 | CYP46A1 1175/4885MAPT 2493/4885NPSR1 2214/4885 |
| US-20130211077-A1 | PROCESS FOR THE SYNTHESIS OF CYCLIC CARBAMATES | PLCG2, PLCG1, PLCB1 | CYP46A1 3608/4885MAPT 4033/4885NPSR1 3194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.